Browse the evidence

GLP-1 receptor agonists (e.g., Semaglutide) are effective for weight loss and metabolic stabilization but cause significant weight regain (rebound) upon discontinuation, necessitating long-term management or transition to surgery.

GLP-1 medications like Semaglutide are powerful tools for weight loss and fixing metabolic issues, but they are not a one-time cure. If you stop taking them, you will likely regain most of the weight. Use them to stabilize your health and weight before considering skin removal surgery, or commit to long-term use if surgery is not an option.

Semaglutide (2.4 mg) reduces the risk of major adverse cardiovascular events (MACE) by 20% in patients with cardiovascular disease and obesity, independent of diabetes status.

If you have heart disease and are overweight, Semaglutide may offer a 20% reduction in your risk of heart attack, stroke, or cardiovascular death, in addition to helping with weight loss. This benefit exists even if you do not have diabetes.

GLP-1 receptor agonists provide cardiovascular and renal benefits, including reduced risk of major adverse cardiovascular events (MACE) and improved heart failure symptoms, independent of weight loss.

GLP-1 and GIP/GLP-1 agonists offer significant cardiovascular and renal benefits, reducing the risk of heart attacks, strokes, and heart failure hospitalizations. These benefits occur independently of weight loss, suggesting direct protective effects on organs. They are recommended for patients with obesity and cardiovascular disease or heart failure.

Obesity and central adiposity drive insulin resistance and hypertension through the dysregulation of adipokines (elevated TNF-α, IL-6, leptin; reduced adiponectin), which activate inflammatory pathways like NF-κB and RAAS.

Excess body fat, especially around the abdomen, releases inflammatory hormones (adipokines) that block insulin action and raise blood pressure. This biological process, driven by cytokines like TNF-α and IL-6, makes weight loss and blood sugar control harder. Addressing obesity through lifestyle changes or medications that target these pathways can improve insulin sensitivity and reduce cardiovascular risk.

Resmetirom (80-100 mg daily) improves histological MASH resolution and fibrosis in patients with F2-F3 fibrosis without requiring significant weight loss, while also lowering LDL cholesterol.

If you have moderate to advanced liver scarring (F2-F3) from metabolic issues, Resmetirom is a new daily pill option. It works by targeting liver-specific thyroid receptors to reduce inflammation and scarring, and it also lowers bad cholesterol. You do not need to lose a lot of weight for it to work on the liver, though diet and exercise are still recommended.

GLP-1 receptor agonists (GLP-1RA) significantly reduce major adverse cardiovascular events (MACE), all-cause mortality, and heart failure hospitalizations in patients with type 2 diabetes and obesity, with specific benefits observed in heart failure with preserved ejection fraction (HFpEF).

If you have Type 2 Diabetes and Obesity, especially with heart issues, GLP-1 medications like Semaglutide or Liraglutide are highly effective. They not only help with weight loss but significantly reduce the risk of heart attacks, strokes, and heart failure hospitalizations. While injections can cause temporary stomach issues, the long-term protection for your heart is substantial. Discuss these options with your doctor, particularly if you have heart failure with preserved ejection fraction.

Smoking cessation leads to significant weight gain and metabolic deterioration, but the cardiovascular benefits of quitting smoking outweigh these risks.

If you smoke, quit. You will likely gain some weight, but this does not cancel out the massive heart health benefits of quitting. Focus on healthy habits to manage weight, but do not let the fear of weight gain stop you from quitting.

Semaglutide 2.4 mg weekly reduces cardiovascular mortality, myocardial infarction, and stroke in overweight/obese patients without diabetes but with cardiovascular disease.

If you have obesity and existing heart disease, even without diabetes, semaglutide 2.4 mg weekly can significantly reduce your risk of heart attack, stroke, and death. This is a critical benefit beyond weight loss. Discuss this with your doctor to see if you qualify for this treatment.

GLP-1 receptor agonists reduce cardiovascular risk in patients with obesity and established cardiovascular disease, even in the absence of diabetes.

For individuals with obesity and existing heart disease, GLP-1 medications like semaglutide can significantly reduce the risk of major cardiovascular events and promote weight loss, even without diabetes. This makes them a valuable tool for comprehensive heart health management.

Glucagon-like peptide-1 (GLP-1) receptor agonists, specifically tirzepatide, significantly reduce AHI and improve hypoxic burden in patients with moderate-to-severe OSA and obesity, independent of or adjunct to CPAP use.

If you have moderate to severe sleep apnea and obesity, ask your doctor about Tirzepatide. Recent clinical trials show it significantly reduces breathing interruptions during sleep and improves oxygen levels, even for those already using CPAP. It has received FDA approval for this use. Be prepared for mild stomach issues initially, which usually subside.

Macronutrient composition (carbohydrate vs fat vs protein ratios) does not significantly impact weight loss outcomes when total caloric intake is controlled, provided the diet is sustainable.

You do not need to follow a specific 'low-carb' or 'low-fat' diet to lose weight. Studies show that when calories are equal, the source of those calories (carbs vs fat vs protein) matters less for weight loss than the total amount. Focus on finding a dietary pattern you enjoy and can stick with long-term.

GLP-1 receptor agonists (GLP-1RAs) significantly reduce major adverse cardiovascular events (MACE) and all-cause mortality in patients with type 2 diabetes, with specific agents like liraglutide and semaglutide demonstrating superior efficacy.

If you have Type 2 Diabetes and are at risk for heart problems, ask your doctor about GLP-1 medications like semaglutide or liraglutide. These drugs not only help control blood sugar but have been proven to significantly lower your risk of heart attack, stroke, and death. Newer oral versions are available if you dislike injections.

SGLT-2 inhibitors (SGLT-2is) reduce major adverse cardiovascular events and renal outcomes in patients with Type 2 Diabetes, with specific agents like empagliflozin and canagliflozin showing significant benefits.

If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about SGLT-2 inhibitors like empagliflozin or canagliflozin. These pills help your body remove excess sugar through urine, which has been shown to significantly protect your heart and kidneys. They are often used alongside metformin.

GLP-1 receptor agonists provide cardiovascular benefits for patients with obesity, even those without diabetes, by reducing the risk of major adverse cardiovascular events.

GLP-1 medications like Semaglutide (2.4 mg weekly) have been shown to reduce the risk of heart attacks, strokes, and cardiovascular death in people with obesity, even if they don't have diabetes. This is a significant benefit beyond weight loss. However, these drugs are expensive and require long-term use.

SGLT2 inhibitors and GLP-1 receptor agonists provide significant cardiovascular and renal protective benefits independent of their blood glucose-lowering effects, making them suitable for treating heart failure and chronic kidney disease in diabetic patients.

If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about SGLT2 inhibitors (like Jardiance or Farxiga) or GLP-1 agonists (like Ozempic or Trulicity). These drugs not only help control blood sugar but also protect your heart and kidneys, which is often more important than just lowering the number on the glucose meter.

GLP-1 receptor agonists (liraglutide, semaglutide) mitigate cardiovascular risks and may reduce atherosclerosis through anti-inflammatory mechanisms.

For patients with type 2 diabetes or cardiovascular disease, GLP-1 receptor agonists like liraglutide and semaglutide offer additional benefits beyond weight loss, including reduced cardiovascular risk and potential mitigation of atherosclerosis through anti-inflammatory effects.

Tirzepatide provides cardiovascular protection by reducing major adverse cardiovascular events (MACE) and improving cardiovascular risk scores in patients with type 2 diabetes and obesity.

Tirzepatide not only helps with weight and blood sugar but also lowers your long-term risk of heart attack and stroke. It improves blood pressure and cholesterol, contributing to overall heart health.

GLP-1 receptor agonists (GLP-1RAs) significantly slow chronic kidney disease (CKD) progression and reduce mortality in patients with type 2 diabetes and CKD.

If you have type 2 diabetes and kidney disease, ask your doctor about GLP-1 receptor agonists like semaglutide. These medications not only help with blood sugar and weight but also significantly slow the progression of kidney damage and reduce the risk of heart problems and death. While side effects like nausea and high costs can be barriers, the long-term benefits for kidney and heart health are substantial and supported by major clinical trials.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly improves metabolic parameters associated with biological aging by restoring glycemic control and reducing visceral adiposity.

If you have type 2 diabetes or obesity, Tirzepatide is an FDA-approved option that directly targets the metabolic dysfunction driving biological aging. It works by mimicking hormones that regulate blood sugar and appetite, leading to significant weight loss and improved glycemic control. Discuss with your doctor if this aligns with your health goals.

Targeting obesity with GLP-1-based therapies reduces major adverse cardiovascular events (MACE) in patients with established atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity, even without diabetes.

If you have heart disease and are overweight or obese, even without diabetes, treating your obesity with semaglutide (2.4 mg weekly) can significantly lower your risk of heart attack, stroke, or cardiovascular death by 20%. This treatment addresses the root metabolic driver of your cardiovascular risk.

Semaglutide reduced major adverse cardiovascular events and all-cause mortality.

Semaglutide may be recommended for patients at risk of cardiovascular events.

No serious adverse events were reported during the trial.

TRE and CR appear to be safe dietary strategies for weight loss in this population.

Tirzepatide significantly increased fat oxidation while decreasing carbohydrate and protein oxidation rates.

Practitioners may leverage TZP's effects on fat oxidation to optimize weight loss protocols.

Tirzepatide showed a favourable safety profile, without increasing the risk of serious adverse events or impacting mortality rates.

Tirzepatide can be used safely in obesity management without significant risk of serious side effects.